74 Gastrointestinal Bleeding Is Not Associated with Pump Speed and Aortic Valve Opening in Patients Supported with the HeartMate II LVAD

2012 ◽  
Vol 31 (4) ◽  
pp. S34 ◽  
Author(s):  
S.R. Patel ◽  
A. Rivera ◽  
J. Patel ◽  
O. Saeed ◽  
M. Camacho-Rivera ◽  
...  
Author(s):  
Clemens Zeile ◽  
Thomas Rauwolf ◽  
Alexander Schmeisser ◽  
Jeremi Kaj Mizerski ◽  
Rüdiger C. Braun-Dullaeus ◽  
...  

AbstractA promising treatment for congestive heart failure is the implementation of a left ventricular assist device (LVAD) that works as a mechanical pump. Modern LVADs work with adjustable constant rotor speed and provide therefore continuous blood flow; however, recently undertaken efforts try to mimic pulsatile blood flow by oscillating the pump speed. This work proposes an algorithmic framework to construct and evaluate optimal pump speed policies with respect to generic objectives. We use a model that captures the atrioventricular plane displacement, which is a physiological indicator for heart failure. We employ mathematical optimization to adapt this model to patient specific data and to find optimal pump speed policies with respect to ventricular unloading and aortic valve opening. To this end, we reformulate the cardiovascular dynamics into a switched system and thereby reduce nonlinearities. We consider system switches that stem from varying the constant pump speed and that are state dependent such as valve opening or closing. As a proof of concept study, we personalize the model to a selected patient with respect to ventricular pressure. The model fitting results in a root-mean-square deviation of about 6 mmHg. The optimization that considers aortic valve opening and ventricular unloading results in speed modulation akin to counterpulsation. These in silico findings demonstrate the potential of personalized hemodynamical optimization for the LVAD therapy.


2016 ◽  
Vol 35 (4) ◽  
pp. S250
Author(s):  
B. Maxhera ◽  
A. Albert ◽  
G. Petrov ◽  
R. Westenfeld ◽  
A. Lichtenberg ◽  
...  

2015 ◽  
Vol 39 (8) ◽  
pp. 704-709 ◽  
Author(s):  
Christopher Hayward ◽  
Choon Pin Lim ◽  
Heinrich Schima ◽  
Peter Macdonald ◽  
Francesco Moscato ◽  
...  

ASAIO Journal ◽  
2006 ◽  
Vol 52 (2) ◽  
pp. 21A
Author(s):  
Laila Hubbert ◽  
Bengt Peterzen ◽  
Stefan Traff ◽  
Henrik Ahn ◽  
Birgitta Janerot-Sjoberg

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Jay D Pal ◽  
Charles T Klodell ◽  
Ranjit John ◽  
Francis Pagani ◽  
Joseph G Rogers ◽  
...  

Objective: Our goal was to determine the operative mortality of isolated implantation of the HeartMate II continuous flow LVAD and the impact of additional concurrent cardiac procedures on patient outcomes. Methods: In a multicenter trial, 279 patients at 33 clinical sites underwent implantation of the HeartMate II continuous flow LVAD as a bridge to transplantation from March 2005 to March 2007. HeartMate II implantation (HM II) was the only procedure required in 172 patients while 80 patients required concurrent cardiac procedures in conjunction with LVAD implantation (HM II+CCP). Results: Preoperative characteristics were similar, but central venous pressure (14.5 vs 11.6 mmHg) was greater for patients requiring concurrent cardiac procedures, suggesting worse right heart dysfunction. Mean cardiopulmonary bypass times increased from 97 to 120 minutes when a concurrent cardiac procedure was performed (p<0.001). Length of stay slightly increased from 23 to 26 days (p=0.17). Overall 30- and 180-day mortality was 5.8% and 13.3% for the HM II group, and 11.3% and 20.0% for the HM II+CCP group. Concurrent valvular procedures increased the risk to 8.5% and 19.1%. Patients who underwent an aortic valve replacement with cardioplegic arrest had a 30-day mortality of 25%, higher than for isolated concurrent mitral (0%) or tricuspid repair (3.3%). Other cardiac procedures were associated with a 30-day mortality of 27.8%. Survival at 180 days was 87% for HMII alone and 80% for HMII+CCP. Conclusion: There is a low 5.8% operative mortality for patients requiring uncomplicated HeartMate II implantation, with no apparent increased risk for concurrent PFO closure, mitral or tricuspid repair. However, concurrent aortic valve and other cardiac procedures are associated with a significantly decreased survival. The increased risk of these procedures must be balanced against the negative impact of uncorrected aortic insufficiency during VAD support.


2017 ◽  
Vol 103 (3) ◽  
pp. e225-e226 ◽  
Author(s):  
Jules Iquille ◽  
Joseph Nader ◽  
Eric Colpart ◽  
Thierry Caus

Sign in / Sign up

Export Citation Format

Share Document